Riskpilot← Back to searchSign inGet full accessVIVOCENS AB
ABActiveOrg 5591606693Husargatan 10 Lgh 47Business and other management consultancy activities · NACE 7020Est. 20180 employees
Revenue 2024
SEK 112K
EBITDA margin
34.8%
Equity ratio
79.9%
Financial strength
Net profit 2024
SEK 39K
0 employees
| Revenue | SEK 112K | — |
| EBITDA | SEK 39K | — |
| Net profit | SEK 39K | — |
| Total assets | SEK 427K | — |
| Equity | SEK 341K | — |
| Employees | 0 | — |
Legal name
VIVOCENS AB
Org number
5591606693
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
30 maj 2018
Share capital
SEK 301 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolagets verksamhet skall omfatta forskning, utveckling, köp och försäljning av tjänster och produkter av bioteknisk och medicinsk karaktär samt annan därmed förenlig rörelse samt att äga och förvalta aktier och andelar i andra företag.
Address
Husargatan 10 Lgh 47
Email
ali.harandi@europe.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 112 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 0 | 0 | 0 | 0 | 39 |
| Depreciation & amort. | — | — | — | — | −0 |
| EBIT | 0 | 0 | 0 | 0 | 39 |
| Net financials | — | — | — | — | — |
| Profit before tax | 0 | 0 | 0 | 0 | 39 |
| Tax | — | — | — | — | −0 |
| Net profit | — | — | — | — | 39 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | — | — | — | — | 427 |
| Equity | — | — | — | — | 341 |
| Long-term debt | — | — | — | — | 0 |
| Short-term debt | — | — | — | — | 86 |
| Total debt | — | — | — | — | 86 |
EBITDA margin
34.8%
This company
15.8%
Market median
+120% vs market
20202024
Equity ratio
79.9%
This company
38.2%
Market median
+109% vs market
20202024
Return on equity
11.4%
This company
18.4%
Market median
+38% vs market
20202024
Net profit margin
34.8%
This company
8.1%
Market median
+330% vs market
20202024
Asset turnover
0.26×
This company
1.12×
Market median
-77% vs market
20202024
Debt / equity
0.25×
This company
0.62×
Market median
+60% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
VM Chief Executive Officer | Chief Executive Officer | 2025 |
AM Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2025 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of VIVOCENS AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Vahid Mohagheghharandi | Chief Executive Officer | 0 companies |
| Ali Mohaghegh Harandi | Deputy Chief Executive Officer | 0 companies |